HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

[Multicenter study of the effectiveness and tolerance of clotiazepam in cardiology].

Abstract
In a phase IV study with clotiazepam 9 cardiologists were involved to treat 86 patients (52 female, 32 male, mean age 51 years) effected by cardiovascular diseases and anxiety. The dosage was 5-10 mg TID, and the treatment lasted for 3 weeks. Variations of the dosage were requested in 21% of patients and generally at the 2nd week of treatment. The safety of clotiazepam was good: only in the 14% of patients side-effects were observed (especially drowsiness 9.3% and asthenia 2.3%). Clotiazepam was judged to be effective in 75% of patients. The Hamilton psychiatric rating scale for anxiety showed a progressive decrease both of the total score and of the scores of every item; the cardiovascular symptoms particularly improved at both the controls.
AuthorsL Colonna, F Cozzi, F Del Citerna, A Di Benedetto, O De Divitiis, F Furlanello, F Milazzotto, M Pittalis, A Taccola
JournalMinerva cardioangiologica (Minerva Cardioangiol) 1990 Jan-Feb Vol. 38 Issue 1-2 Pg. 45-9 ISSN: 0026-4725 [Print] ITALY
Vernacular TitleStudio policentrico sull'efficacia e tollerabilità del clotiazepam in cardiologia.
PMID1971433 (Publication Type: Clinical Trial, English Abstract, Journal Article, Multicenter Study)
Chemical References
  • Azepines
Topics
  • Adolescent
  • Adult
  • Aged
  • Anxiety (complications, drug therapy)
  • Azepines (administration & dosage, therapeutic use)
  • Cardiovascular Diseases (psychology)
  • Drug Evaluation
  • Female
  • Humans
  • Male
  • Middle Aged
  • Multicenter Studies as Topic
  • Psychiatric Status Rating Scales

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password: